Limits...
SEMA6D Expression and Patient Survival in Breast Invasive Carcinoma.

Chen D, Li Y, Wang L, Jiao K - Int J Breast Cancer (2015)

Bottom Line: We found 6-gene expression profile that can be used as such predictors.Our study provides evidences for the first time that breast invasive carcinoma may contain a subtype based on SEMA6D expression.The expression of SEMA6D gene may play an important role in promoting patient survival, especially among triple negative breast cancer patients.

View Article: PubMed Central - PubMed

Affiliation: Division of Preventive Medicine, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL 35294, USA ; Comprehensive Cancer Center, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL 35294, USA.

ABSTRACT
Breast cancer (BC) is the second most common cancer diagnosed in American women and is also the second leading cause of cancer death in women. Research has focused heavily on BC metastasis. Multiple signaling pathways have been implicated in regulating BC metastasis. Our knowledge of regulation of BC metastasis is, however, far from complete. Identification of new factors during metastasis is an essential step towards future therapy. Our labs have focused on Semaphorin 6D (SEMA6D), which was implicated in immune responses, heart development, and neurogenesis. It will be interesting to know SEMA6D-related genomic expression profile and its implications in clinical outcome. In this study, we examined the public datasets of breast invasive carcinoma from The Cancer Genome Atlas (TCGA). We analyzed the expression of SEMA6D along with its related genes, their functions, pathways, and potential as copredictors for BC patients' survival. We found 6-gene expression profile that can be used as such predictors. Our study provides evidences for the first time that breast invasive carcinoma may contain a subtype based on SEMA6D expression. The expression of SEMA6D gene may play an important role in promoting patient survival, especially among triple negative breast cancer patients.

No MeSH data available.


Related in: MedlinePlus

Number of significant genes between the two comparisons: H versus L and M versus L. FC: fold change.
© Copyright Policy - open-access
Related In: Results  -  Collection


getmorefigures.php?uid=PMC4417987&req=5

fig3: Number of significant genes between the two comparisons: H versus L and M versus L. FC: fold change.

Mentions: We further examined SEMA6D levels by including SEMA6D-medium versus SEMA6D-low expression group comparison. As shown in the Venn diagram in Figure 3, 58 unique genes are significant between SEMA6D-medium and SEMA6D-low patients, while 2,357 genes are significant in SEMA6D-high versus SEMA6D-low expression comparison. This suggests that higher level of SEMA6D expression may lead to more significant changes, as evidenced by an increased number of genes with significant changes. This also suggests that the function of SEMA6D may be dependent on the expression level or that SEMA6D-induced functional effects are dose-dependent.


SEMA6D Expression and Patient Survival in Breast Invasive Carcinoma.

Chen D, Li Y, Wang L, Jiao K - Int J Breast Cancer (2015)

Number of significant genes between the two comparisons: H versus L and M versus L. FC: fold change.
© Copyright Policy - open-access
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC4417987&req=5

fig3: Number of significant genes between the two comparisons: H versus L and M versus L. FC: fold change.
Mentions: We further examined SEMA6D levels by including SEMA6D-medium versus SEMA6D-low expression group comparison. As shown in the Venn diagram in Figure 3, 58 unique genes are significant between SEMA6D-medium and SEMA6D-low patients, while 2,357 genes are significant in SEMA6D-high versus SEMA6D-low expression comparison. This suggests that higher level of SEMA6D expression may lead to more significant changes, as evidenced by an increased number of genes with significant changes. This also suggests that the function of SEMA6D may be dependent on the expression level or that SEMA6D-induced functional effects are dose-dependent.

Bottom Line: We found 6-gene expression profile that can be used as such predictors.Our study provides evidences for the first time that breast invasive carcinoma may contain a subtype based on SEMA6D expression.The expression of SEMA6D gene may play an important role in promoting patient survival, especially among triple negative breast cancer patients.

View Article: PubMed Central - PubMed

Affiliation: Division of Preventive Medicine, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL 35294, USA ; Comprehensive Cancer Center, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL 35294, USA.

ABSTRACT
Breast cancer (BC) is the second most common cancer diagnosed in American women and is also the second leading cause of cancer death in women. Research has focused heavily on BC metastasis. Multiple signaling pathways have been implicated in regulating BC metastasis. Our knowledge of regulation of BC metastasis is, however, far from complete. Identification of new factors during metastasis is an essential step towards future therapy. Our labs have focused on Semaphorin 6D (SEMA6D), which was implicated in immune responses, heart development, and neurogenesis. It will be interesting to know SEMA6D-related genomic expression profile and its implications in clinical outcome. In this study, we examined the public datasets of breast invasive carcinoma from The Cancer Genome Atlas (TCGA). We analyzed the expression of SEMA6D along with its related genes, their functions, pathways, and potential as copredictors for BC patients' survival. We found 6-gene expression profile that can be used as such predictors. Our study provides evidences for the first time that breast invasive carcinoma may contain a subtype based on SEMA6D expression. The expression of SEMA6D gene may play an important role in promoting patient survival, especially among triple negative breast cancer patients.

No MeSH data available.


Related in: MedlinePlus